Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiogenesis is the physiological process by which new blood vessels form from pre-existing vessels. This process is essential for normal development, wound healing, and reproductive functions, but it also plays a critical role in pathological conditions such as tumor growth and metastasis. It involves a tightly regulated sequence of events including endothelial cell (EC) activation, proliferation, migration, differentiation into tip and stalk cells, lumen formation, vessel maturation, and stabilization. Key molecular players include VEGF, FGF, PDGF, Angiopoietins, TGF-β, MMPs, and integrins. Targeting components of the angiogenesis pathway is a major therapeutic strategy in oncology.
Inhibition of pro-angiogenic signaling pathways, primarily targeting VEGF and its receptors, or other components like angiopoietins or downstream kinases. Some agents target multiple tyrosine kinases involved in angiogenesis.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiogenesis Pathway.